BioAsset

Insights / All articles

Research

CRISPR’s Fatal Test: Intellia’s In-Vivo Reality Check

By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides

Intellia Therapeutics has paused its Phase III in vivo gene-editing trial after a patient, in their early 80s and with other medical conditions, died from liver complications. The FDA has placed a clinical hold on the trial, and the stock closed at $9.52, down 22.73% on the day from a previous close of $12.32.

Intellia’s therapy uses in vivo CRISPR editing to silence the TTR gene, which causes a rare protein misfolding disease called transthyretin amyloidosis. It is one of the first human trials using CRISPR inside the body rather than outside it. That is why the death matters beyond one company: it raises new questions about the safety of delivering CRISPR edits directly to human organs.

Growth and risk together

The U.S. gene-editing market has expanded rapidly, rising from $5B in 2020 to $53B by 2025. That growth reflects surging investment, new clinical programs and early signs of commercialization.

Reported safety incidents have climbed in parallel, from about six in 2020 to roughly 20 in 2025. More in vivo trials mean greater visibility into potential side effects such as liver toxicity, immune response and off-target DNA edits. Regulatory focus is shifting with it: the FDA is expected to tighten oversight on CRISPR-based therapies, particularly for direct human applications. Investors now weigh both promise and risk more carefully.

What to take from it

Intellia’s setback highlights the dangers of fast-paced innovation, but it also shows the importance of long-term resilience in biotech. The death in the trial is tragic, and it does not erase the progress of gene editing. Every major advancement in medicine has faced moments of risk.

For investors, regulatory delays and increased inspection could lead to short-term instability, but companies that prioritize transparency and data integrity will emerge stronger. For scientists, these events reinforce the need for improved delivery systems, safer vectors and long-term patient monitoring protocols before commercial rollout. For the public, the future of CRISPR depends on trust, and further education, realistic expectations and honest communication between companies, regulators and patients will shape public confidence.

The setback is not an end, it is a recalibration. The gene-editing field will evolve, but how it learns from this moment will define its credibility for years to come.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.